Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
ASND missed Q2 sales estimates, reporting $38.76 million. Yorvipath’s U.S. pricing is $285,000/patient/year, higher than expected. Skytrofa's lower guidance delays breakeven to 2024-2025. Analysts maintain Overweight rating but lower price target to $170. Ascendis expects upcoming data from TransCon CNP trial.
- ASND missed Q2 sales estimates, reporting $38.76 million.
- Yorvipath’s U.S. pricing is $285,000/patient/year, higher than expected.
- Skytrofa's lower guidance delays breakeven to 2024-2025.
- Analysts maintain Overweight rating but lower price target to $170.
- Ascendis expects upcoming data from TransCon CNP trial.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.